GB2396302A - Magnetic field enhancement of tumor treatment - Google Patents

Magnetic field enhancement of tumor treatment Download PDF

Info

Publication number
GB2396302A
GB2396302A GB0408373A GB0408373A GB2396302A GB 2396302 A GB2396302 A GB 2396302A GB 0408373 A GB0408373 A GB 0408373A GB 0408373 A GB0408373 A GB 0408373A GB 2396302 A GB2396302 A GB 2396302A
Authority
GB
United Kingdom
Prior art keywords
magnetic field
tumor treatment
field enhancement
tumor
mtesla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0408373A
Other versions
GB2396302B (en
GB0408373D0 (en
Inventor
Robert E Sandstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB0408373D0 publication Critical patent/GB0408373D0/en
Publication of GB2396302A publication Critical patent/GB2396302A/en
Application granted granted Critical
Publication of GB2396302B publication Critical patent/GB2396302B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Treatment Devices (AREA)

Abstract

A method of treating a tumor, comprising creating an elevated concentration of free radicals in said tumor (22) and creating a magnetic field (20) that traverses said tumor (22) and that inhibits the recombination of said free radicals in said tumor. A magnetic field of 0.1 mTesla to 10 mTesla is generally used for this purpose.

Description

GB 2396302 A continuation (74) Agent and/or Address for Service:
Murgitroyd & Company Scotland House, 165-169 Scotland Street, GLASGOW, G5 8PL, United Kingdom
GB0408373A 2001-10-11 2002-10-09 Magnetic field enhancement of tumor treatment Expired - Lifetime GB2396302B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32808501P 2001-10-11 2001-10-11
US34927002P 2002-01-18 2002-01-18
PCT/US2002/032444 WO2003030722A2 (en) 2001-10-11 2002-10-09 Magnetic field enhancement of tumor treatment

Publications (3)

Publication Number Publication Date
GB0408373D0 GB0408373D0 (en) 2004-05-19
GB2396302A true GB2396302A (en) 2004-06-23
GB2396302B GB2396302B (en) 2006-05-31

Family

ID=26986208

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0408373A Expired - Lifetime GB2396302B (en) 2001-10-11 2002-10-09 Magnetic field enhancement of tumor treatment

Country Status (4)

Country Link
AU (1) AU2002343495A1 (en)
CA (1) CA2463491C (en)
GB (1) GB2396302B (en)
WO (1) WO2003030722A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2855067B1 (en) 2003-05-20 2005-06-24 Emery Sa SNOW SURF MOUNTING
CN107362445A (en) * 2017-08-30 2017-11-21 东北师范大学 Anticancer targeting medicine points to electrostatic field resultant vector intensifier
WO2019120489A1 (en) * 2017-12-19 2019-06-27 Medical Development Technologies S.A. Heatable implant device for tumor treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665898A (en) * 1984-05-23 1987-05-19 Maxwell Laboratories, Inc. Malignancy treatment
US5156587A (en) * 1983-09-01 1992-10-20 Montone Liber J Method for treating malignant cells
US6261831B1 (en) * 1999-03-26 2001-07-17 The United States Of America As Represented By The Secretary Of The Air Force Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039988B1 (en) * 1980-04-29 1984-05-23 Electro-Biology, Inc Apparatus for treating an intact animal organism bearing a neoplastic process and undergoing drug treatment
WO1997004830A1 (en) * 1995-07-28 1997-02-13 Gray James R Use of a polarizing field to modify the efficacy of a bioactive agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156587A (en) * 1983-09-01 1992-10-20 Montone Liber J Method for treating malignant cells
US4665898A (en) * 1984-05-23 1987-05-19 Maxwell Laboratories, Inc. Malignancy treatment
US6261831B1 (en) * 1999-03-26 2001-07-17 The United States Of America As Represented By The Secretary Of The Air Force Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat

Also Published As

Publication number Publication date
GB2396302B (en) 2006-05-31
WO2003030722A2 (en) 2003-04-17
GB0408373D0 (en) 2004-05-19
WO2003030722A3 (en) 2003-07-03
CA2463491A1 (en) 2003-04-17
CA2463491C (en) 2011-07-26
AU2002343495A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
HU9602721D0 (en) Use of serotonin antagonists (5ht3) for treating fibromyalgia
AU2210400A (en) Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
TR199801348T2 (en) Heterosyclic condensate morphinoid t�revleri (II).
BR9707233A (en) Phenanthridines
IL144559A0 (en) Antibodies for cancer therapy and diagnosis
EP0885958A4 (en) Method for treating biopolymers, microorganisms or materials by using more than one type of magnetic particles
DE59403670D1 (en) METHOD FOR SUBCRITICAL DRYING OF AEROGELS
DK0889886T5 (en) Novel, 6-position substituted phenanthridines
TR199801302T2 (en) Substituted aza and diazacyclopentane and cyclooctane compounds.
ATE234300T1 (en) BENZONAPHTHYRIDINES AS BRONCHIAL THERAPEUTICS
ATE301329T1 (en) PARTICLES
GB2396037A (en) Method and system for logging into and providing access to a computer system via a communications network
AU7950000A (en) Imidazol-4-ylmethanols use as inhibitors of steroid c17-20 lyase
CA2366606A1 (en) Method and arrangement for introduction of sewage pre-treatment upstream of sewage treatment facility
MXPA03004517A (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis.
GB2424554A (en) Dynamic emi (electromagnetic interference) management
DE69837153D1 (en) PREVENTING CELL GROWTH IN A WATER
GB2396302A (en) Magnetic field enhancement of tumor treatment
AU3902901A (en) Method for treating solid waste with an organic fraction
MXPA02011558A (en) Novel mmp 2 mmp 9 inhibitors.
HK1020211A1 (en) Molecular model for vla-4 inhibitors vla-4
DE69903716D1 (en) COMBINATION OF AN INVERSE AGONIST OF THE GABA-A ALPHA-5 RECEPTOR SUBTYPS AND NICOTINERGE AGONISTS
BR0204057A (en) Processes for terahertz generation
PL312777A1 (en) Method of removal of unwanted colouring of hydrochloric acid
TR199701613T1 (en) Melatonin agonists for the treatment of benign prostatic hyperplasia.

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20221008